Cambridge, MA's NeuroPhage banked an additional $10 million in Series D cash, bringing its latest round to $27 million and filling out the biotech's war chest as it marches toward the clinic with a treatment for neurodegenerative disease.
In a sign of the times, leading life sciences venture maven David Mott and his colleagues at New Enterprise Associates have begun raising a whopping $2.5 billion venture fund--less than three years after rolling out its latest fund with $2.6 billion.
Fountain Healthcare Partners put together an €85 million ($101 million) new purse, money the Irish investor plans to pour into biotech startups.
Danish biotech Orphazyme raised a €20 million ($24 million) B round to fund its work on rare lysosomal storage disorders, tapping an investor syndicate that includes Novo Nordisk's venture arm as it rolls toward Phase II trials.
Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.
Checkpoint inhibitors, designed to help the immune system better identify and attack cancer, have become the consensus next big things in oncology. But startup Surface Oncology is looking beyond their transformative promise with eyes on the next generation of immunotherapies, chasing some newly identified targets and raising $35 million to get rolling.
Switzerland's Genkyotex has gathered together $21 million in its latest venture round, which is designed to get their lead NOX inhibitor through a midstage proof-of-concept study and right up to the threshold of a possible IPO as they beef up the pipeline.
Blend Therapeutics, a biotech with ties to MIT serial entrepreneur Robert Langer, has hauled in $21 million in new financing to flesh out a novel approach to cancer treatment.
You can count Seres Health among the wave of biotech companies starting the year with a big new round of venture cash. The Cambridge, MA-based biotech--which has set out to make its reputation in the trendy new microbiome space--said today that it raised $65 million from Nestle Health Science.
South San Francisco oncology specialist CytomX raised a $20 million C round to advance its in-house pipeline of novel cancer treatments, with partner Pfizer pouring in the lion's share of the new cash.